These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 22386757

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comment on: Possible miliary tuberculosis during adalimumab therapy with negative gamma-IFN release assays.
    Mangat P, Taylor P, Abraham S.
    Rheumatology (Oxford); 2009 Sep; 48(9):1177-8; author reply 1178. PubMed ID: 19567659
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Distal esophageal involvement in Crohn disease: short treatment with adalimumab.
    Musto D, Martorelli L, Cirillo A, Selvaggi F, Esposito P, Russo MI, Riegler G.
    Endoscopy; 2010 Sep; 42 Suppl 2():E299. PubMed ID: 21113880
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Disseminated tuberculosis after anti-TNFalpha treatment.
    Agarwal R, Srinivas R, Gupta D.
    Lancet; 2007 Aug 18; 370(9587):564; author reply 565. PubMed ID: 17707746
    [No Abstract] [Full Text] [Related]

  • 12. [The cost effectiveness of adalimumab in Crohn's disease (review of foreign pharmacoeconomic studies)].
    Rudakova AV.
    Eksp Klin Gastroenterol; 2011 Aug 18; (9):113-9. PubMed ID: 22629787
    [No Abstract] [Full Text] [Related]

  • 13. [Efficacy and safety of Adalimumab in Crohn's disease].
    Serghini M, Haddad W, Jeddi H, Karoui S, Ben Mustapha N, Kallel L, Fekih M, Matri S, Boubaker J, Filali A.
    Tunis Med; 2012 Feb 18; 90(2):101-7. PubMed ID: 22407620
    [Abstract] [Full Text] [Related]

  • 14. Oropharyngeal and proximal esophageal involvement during adalimumab treatment of Crohn disease.
    Nguyen KD, Alexis R, Schwarz SM.
    J Pediatr Gastroenterol Nutr; 2010 Feb 18; 50(2):225-6. PubMed ID: 19841594
    [No Abstract] [Full Text] [Related]

  • 15. TNF-α inhibitor (adalimumab) induced psoriasis: a case report.
    Al-Mutairi A, Elkashlan M, Al-Fayed HM, Swayed M.
    Australas J Dermatol; 2012 May 18; 53(2):157. PubMed ID: 22571571
    [No Abstract] [Full Text] [Related]

  • 16. Development of the nephrotic syndrome during treatment of Crohn's disease with adalimumab.
    Gupta A, Pendyala P, Arora P, Sitrin MD.
    J Clin Gastroenterol; 2011 Mar 18; 45(3):e30-3. PubMed ID: 20975576
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tuberculous monoarthritis after treatment with adalimumab in Crohn's disease.
    Martínez-Caselles A, Martínez-Pascual C, Muñoz-Tornero M, Sánchez-Torres A, Carballo-Álvarez F.
    Rev Esp Enferm Dig; 2012 Mar 18; 104(3):157-8. PubMed ID: 22449164
    [No Abstract] [Full Text] [Related]

  • 19. Opportunistic infection-associated immune reconstitution syndrome in transplant recipients.
    Sun HY, Singh N.
    Clin Infect Dis; 2011 Jul 15; 53(2):168-76. PubMed ID: 21690625
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.